VolitionRx Sponsors Innovative Webinar on Epigenetic Modifications and Drug Discovery
Volition Sponsors Upcoming GenomeWeb Webinar
VolitionRx Limited (NYSE AMERICAN: VNRX) is set to make waves in the field of epigenetics with their upcoming sponsorship of a GenomeWeb webinar entitled "Beyond the Genome Measuring Epigenetic Modifications Across Matrices for Biomarker and Drug Discovery". The event is scheduled for Wednesday, October 8, and promises to be an enlightening session for professionals in drug development and cancer research.
Webinar Highlights
Date and Time
- - Date: Wednesday, October 8
- - Time: 8 AM PT / 11 AM ET / 5 PM CET
Featured Speakers
- - Dr. Eric Ariazi: A translational cancer biologist will highlight major epigenetic pathways and their implications for health and disease.
- - Dr. Marielle Herzog: The RD director at Belgian Volition will present various case studies, demonstrating the robust capabilities of the Nu.Q assays developed according to CLSI guidelines.
In this webinar, attendees can expect a deep dive into epigenetic pathways through practical case studies that will showcase the effectiveness of Nu.Q assays in clinical and preclinical settings.
Understanding Nu.Q® Discover
Volition's innovative Nu.Q® Discover program equips scientists and drug developers with cutting-edge assays for rapid epigenetic profiling. The program is designed to facilitate disease model development and clinical studies, making it a crucial resource in the realm of pharmaco-epigenetics. By leveraging proprietary nucleosome quantification technology, the Nu.Q® Discover program serves as a pivotal tool for understanding variations in drug responses, ultimately aiming to enhance therapeutic outcomes.
The insights shared during this event are expected to shed light on the promising future of cancer treatment through immunotherapy and pharmacologic interventions targeting EZH2 and EED — subunits of the polycomb repressor complex 2 (PRC2). Strategies revolving around these targets are anticipated to pave the way for more effective cancer therapies.
Volition's Commitment to Health
Founded with a mission to promote earlier detection and better monitoring of life-threatening diseases, VolitionRx is pioneering advancements in epigenetics. The company's research and development pursuits extend across international borders, with facilities in Belgium and the United States, confirming its standing as a multi-national entity committed to enhancing patient outcomes globally.
Their blood tests are being developed not only to diagnose various cancers but also other diseases linked to NETosis, such as sepsis. By focusing on early diagnostics and research, Volition aims to not only prolong lives but also profoundly improve the quality of life for patients.
This upcoming webinar is indicative of Volition's dedication to fostering discussions that will lead to significant advancements in epigenetic research and drug development. If you are engaged in the fields of oncology or epigenetics, this is an event not to be missed.
To register, visit the link provided in the original announcement or check out Volition's website for more details.
Contact Information
For media inquiries: Louise Batchelor, Volition - [email protected]
Investor Relations: Jeremy Feffer, LifeSci Advisors - [email protected]
Safe Harbor Statement: This press release includes forward-looking statements that may involve risks and uncertainties, with actual results differing materially from those conveyed. For detailed disclosures, please refer to Volition’s reports filed with the Securities and Exchange Commission.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.